Abstract
In patients with non–small-cell lung cancer (NSCLC), resistance to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is usually mediated by the T790M EGFR gene mutation. Rociletinib is an oral EGFR mutant-selective inhibitor that has demonstrated activity against EGFR -mutated NSCLC with or without T790M mutation. Investigators have now conducted an industry-supported, phase 1–2 dose-escalation and expansion trial of rociletinib in patients with EGFR -mutated NSCLC who acquired resistance to EGFR TKIs; the expansion segment …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
